Glioma

ORIGINAL ARTICLE
Year
: 2018  |  Volume : 1  |  Issue : 3  |  Page : 104--110

YKL-40 in high-grade glioma: Prognostic value of protein versus mRNA expression


Yu-Hang Zhao1, Zhi-Yong Pan1, Ze-Fen Wang2, Chao Ma1, Hong Weng3, Zhi-Qiang Li4 
1 Department of Neurosurgery, Zhongnan Hospital, Wuhan University, Wuhan, Hubei, China
2 Department of Physiology, School of Basic Medical Sciences, Wuhan University, Wuhan, Hubei, China
3 Center for Evidence-based and Translational Medicine, Zhongnan Hospital, Wuhan University, Wuhan, Hubei, China
4 Department of Neurosurgery, Laboratory of Neuro-Oncology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei, China

Correspondence Address:
Dr. Zhi-Qiang Li
Department of Neurosurgery, Zhongnan Hospital, Wuhan University, Wuhan 430072, Hubei
China

Background: YKL-40 has been reported to be associated with the prognosis of glioma patients. However, expression of YKL-40 was detected at protein or mRNA level in different studies. This may result in conclusion bias. This study is to investigate the prognostic value of increased YKL-40 protein versus mRNA expression in glioma patients. Methods: A comprehensive systematic search and review were performed using PubMed, EMBASE, and NKI databases to identify literature (published before May 1, 2018) that evaluated the association between YKL-40 and survival in glioma patients. Results: Thirteen relevant studies, involving 2139 patients, were included in this study. Elevated YKL-40 expression was associated with worse overall survival (OS) in glioma patients (hazard ratio [HR] = 1.44, 95% confidence interval [CI]: 1.27–1.63, P < 0.001), especially in high-grade glioma (anaplastic glioma: HR = 1.37, 95% CI: 1.09–1.74, P = 0.008; glioblastoma multiform: HR = 1.52, 95% CI: 1.33–1.73, P < 0.001). The increased YKL-40 protein level in serum (detected by ELISA) or in tumor tissues (detected by immunohistochemistry) was associated with worse OS (ELISA: HR = 1.43, 95% CI: 1.29–1.59, P < 0.001; immunohistochemistry: HR = 1.52, 95% CI: 1.20–1.93, P = 0.001). However, the association between elevated YKL-40 mRNA level (detected by real-time PCR) with worse OS was not significant (HR = 1.44, 95% CI: 0.73–2.83, P = 0.29, I2 = 68.3%). In addition when status of IDH1 mutation or/and O6-methylguanine-DNA methyltransferase promoter was incorporated as multivariate, increased expression level of YKL-40 was not associated with poorer survival (HR = 1.39, 95% CI: 0.99–1.93, P = 0.055). Conclusion: YKL-40 protein level, rather than mRNA level, may be a valuable biomarker to assess the prognosis in glioma patients.


How to cite this article:
Zhao YH, Pan ZY, Wang ZF, Ma C, Weng H, Li ZQ. YKL-40 in high-grade glioma: Prognostic value of protein versus mRNA expression.Glioma 2018;1:104-110


How to cite this URL:
Zhao YH, Pan ZY, Wang ZF, Ma C, Weng H, Li ZQ. YKL-40 in high-grade glioma: Prognostic value of protein versus mRNA expression. Glioma [serial online] 2018 [cited 2023 Feb 3 ];1:104-110
Available from: http://www.jglioma.com/article.asp?issn=2589-6113;year=2018;volume=1;issue=3;spage=104;epage=110;aulast=Zhao;type=0